Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

Slides:



Advertisements
Similar presentations
CB-1 MDS Classification and Prognosis John M. Bennett, MD University of Rochester Medical Center Hematomorphologist Chair, MDS Foundation.
Advertisements

Myelodysplastic Syndromes
The Patient Experience With Systemic Lupus Erythematosus
Primary Care Challenges in Depression - To Treat or Refer?
Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.
NOACs for Cancer-Associated Thrombosis:
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Advances in Managing Inhibitors in Patients With Hemophilia A
Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome
Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.
Protecting Patients With Varicose Veins
Epidemiology Venous Pathophysiology Etiology.
Advances in Dry Eye.
Before and After: Patient Cases in Onychomycosis
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Current and Future Goals in the Treatment of Relapsed CLL
Treating Transplant-Ineligible Patients With Multiple Myeloma
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Myelodysplastic Syndromes
How Can we Improve Outcomes for the Elderly Patient with AML?
Activity Goals. Activity Goals Case Presentation.
What Is Myelodysplastic Syndrome?
Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.
MDS: Introduction. Supportive Care in the Treatment of Lower-Risk Myelodysplastic Syndromes.
HCV Protease Inhibitors in Clinical Practice
From Symptom Management to Communication in Advanced GI Cancers
WHO Clinical Classification of PH Complex Cases in PH.
Antithrombotic Protection in CAD and HF
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Navigating New Oral Treatment Algorithms in CLL
Charting Progress in MS Treatment:
Mutational Testing to Select Novel Targeted Therapies in AML
The New Landscape of ABSSTI Treatment Opportunities to Improve Patient Care.
Advancing the Treatment of IBD With Biologics
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
When Is Biologic Therapy Appropriate for HS?
Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Personalizing Management in the Care of Patients With Advanced Sarcoma
Future Directions in Myelofibrosis: Implications of Emerging Approaches.
The Evolving Treatment Landscape in Atopic Dermatitis
Navigating Treatment Options in PAH
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis
MYELODYSPLASTIC SYNDROME: prognosis & treatment options
Systemic Lupus Erythematosus
Cancer-Associated Thrombosis
Implications of Emerging Treatments for Beta-Thalassemia
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
New ELN Recommendations
A Guideline-Based Approach to HCV Care
HCV Protease Inhibitors in Clinical Practice
The Changing Field of Melanoma: Ipilimumab.
Communicating With Your Patients About Major Depressive Disorder
Managing Anemia in Lower-Risk MDS
Incorporating Prostacyclins Into Practice
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Novel Concepts in the Management of RCC
Improving Adherence to Antiplatelet Therapy After an ACS Event
Perspective on the Multidisciplinary Management of PAH
Saving the Day.
Renal Function and Myeloma Therapeutics
AMD Therapy: Where Are We Now and Where Are We Going?
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
Merging the Art and Science of Managing nOH in Clinical Practice
Risk Stratification in MDS
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS

Case 1

Etiology of Anemia

MDS Mutation Landscape

IPSS for MDS

The IPSS-R

WHO and WPSS Scoring System

MD Anderson Model of Prognosis for Patients With Low-Risk MDS

Case (cont)

Treat the Symptoms: Supportive Care

Case (cont)

Current "Standard" Therapy for MDS

Iron Chelation

Lenalidomide for Low-Risk MDS

Novel Agents: Siltuximab and Sotatercept

Case: Further Treatment Options

Hypomethylating Agents

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)